image: Scientists Miquel Duran (left) and Patrick Aloy studied the molecular mechanisms of drug side effects. view more
Credit: IRB Barcelona
Barcelona, Friday 19 April 2013.- Yellow vision, pseudo-pulmonary obstruction, involuntary body movements, respiratory paralysis. These are some of the 1,600 known side effects (SEs) produced by drugs. Adverse effects are one of the main causes of hospital admission in the west. These effects are difficult to predict, and in practice specific assays are required to test the safety of agents in pre-clinical phases, thus these effects are often not discovered until the drug has been launched. A study published by scientists at the Institute for Research in Biomedicine (IRB Barcelona) seeks to fill this information gap. The objective of the study is to shed light on the molecular bases of SEs and provide medical chemists with the tools to design safer drugs and to predict their effects. The study collects and proposes molecular hypotheses for 1,162 side effects. This information, which is about to be tested experimentally, is now available to the scientific community through the most recent issue of the specialized journal Chemistry and Biology, part of the Cell group.
The researchers Miquel Duran and Patrick Aloy collated all the drugs that cause each known SE. Next, they studied the proteins with which they interact and their chemical structure. "For most of the side effects we have a biological hypothesis, and for many of these cases we also have chemical information about the drug, which may be useful to predict a specific secondary effect," explains ICREA researcher Patrick Aloy, head of the "Structural Bioinformatics and Network Biology" at IRB Barcelona. Of the 1,162 SEs for which they have found a molecular description, 446 can be explained solely on the basis of biology and 68 only on the basis of chemistry, while for 648 (56%) both biological and chemical considerations are required.
Some examples: Xanthopsia and Buccoglossal Syndrome
One of the SEs described is Buccoglossal Syndrome, a disorder involving involuntary movements of the body and caused by six different drugs. The researchers propose that drugs whose structures include a piperazine ring and, in addition, interact with the receptors 5-HT2A and/or DRD2 are more likely to cause this syndrome. "This is one of the examples where we need a biological and chemical explanation," says Miquel Duran, a chemist doing his PhD in Aloy's lab, and first author of the paper. "Another interesting case is Xanthopsia, a predominance of yellow in the vision, a condition supposedly experienced by Van Gogh", explain the researchers. "In this case we do not suspect any related protein but observe that there are chemical structures that can cause this disorder, which we have annotated in 12 drugs that include this condition as a possible side effect" .
"We are providing the scientific community with lists of proteins and the chemical features associated with SEs. We refer to these as "alerts": they can be used by drug design experts to try to avoid certain interactions and/or structures in order to develop safer drugs," says Aloy.
For these scientists, it is necessary to combine biology and chemistry in order to determine what may be causing a given SE. "In practice, and for each unwanted effect, there is a biological part that we know, but this part does not offer a complete picture of the mechanism and perhaps we will be able to fill this gap by "looking at" the chemical structure," upholds Duran. "The multidisciplinarity provided by IRB Barcelona allows us to start studies with these characteristics, which require the convergence of several fields to achieve a more complete understanding," says Dr. Aloy, an expert in systems biology.
Reference article:
Analysis of Chemical and Biological Features Yields Mechanistic Insights into Drug Side Effects
Miquel Duran-Frigola and Patrick Aloy
Chemistry and Biology (2013): http://dx.doi.org/10.1016/j.chembiol.2013.03.017
Institute for Research in Biomedicine (IRB Barcelona)
Founded in 2005 by the Government of Catalonia and the University of Barcelona, the Institute for Research in Biomedicine (IRB Barcelona) is one of eight centres in Spain to be first recognised by the Ministry of Economy and Competitiveness as a "Severo Ochoa Centre of Excellence". The 22 groups hosted by the institute are devoted to basic and applied research at the interface between molecular and cellular biology, structural and computational biology, and chemistry, with experts in proteomics, genomics, biostatistics, and advanced digital microscopy. The research at IRB Barcelona is organised into five programmes, which work together with the common goal of conducting multidisciplinary projects that address important biomedical problems affecting our society, with special emphasis on cancer and metastasis. The institute is home to approximately 430 employees from 38 countries. IRB Barcelona's ultimate objective is to translate research results to the clinic and has already established three biotechnology spin-off companies to this end. The institute is located in the Barcelona Science Park (PCB), in the Diagonal Campus of the University of Barcelona. Director: Dr. Joan J. Guinovart. Adjunct director: Dr. Joan Massagué. http:http://www.irbbarcelona.org
Journal
Chemistry & Biology